Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
RALEIGH, N.C., Oct. 09, 2017 -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its third quarter 2017 results after the market closes on Wednesday, October 25, 2017. The Company will also host a conference call on Thursday, October 26, 2017 at 8:00 a.m. (ET) to discuss the results with members of the investment community.
To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 98635318. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 98635318.
A live audio broadcast will be available on the investor relations section of the PRA Health Sciences website. Following the teleconference, an audio playback of the call will be available at the same website.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes More than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and over 14,000 employees worldwide. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. To learn more about PRA, please visit www.prahs.com.
INVESTOR INQUIRIES: [email protected]
